![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260922_Shanghai_RAAS_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Shanghai RAAS<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Progression (Source Gap Catch-Up)<\/p>\n Modality<\/strong><\/p>\n Monoclonal Antibody<\/p>\n Asset<\/strong><\/p>\n SR604<\/p>\n Target<\/strong><\/p>\n Activated Protein C<\/p>\n Disease Area<\/strong><\/p>\n Hemophilia A and B<\/p>\n Shanghai RAAS disclosed on 17 September that SR604 entered a single arm multicenter Phase 3 study for prophylaxis in hemophilia A or B patients with or without inhibitors. The registered dose is 0.4 mg per kg every four weeks. SR604 is a humanized antibody that binds activated protein C and suppresses its anticoagulant activity, a mechanism intended to rebalance coagulation independent of factor replacement.<\/p>\n The company stated that Phase 1 and 2 work met its prespecified primary endpoint and that core data were presented at an international meeting, but the exchange filing did not provide annualized bleeding rate, treated bleed, thrombosis, laboratory or subgroup results. Phase 3 entry therefore confirms development progression, not efficacy magnitude.<\/p>\n SR604 is also in Phase 2 for von Willebrand disease and congenital factor VII deficiency. The latter was formally included in a CDE rare disease development pilot. The Phase 3 hemophilia trial is single arm, making baseline bleed history and standardized rescue treatment important for interpretation.<\/p>\n Interpretation one is that activated protein C inhibition can provide infrequent prophylaxis across hemophilia types and inhibitor status. Monthly dosing and factor independent activity could reduce burden. Against this, rebalancing hemostasis can create thrombosis risk, and potency may vary with background factor, inhibitor titer and concomitant bypassing agents.<\/p>\n Interpretation two is that one mechanism can serve multiple rare bleeding disorders. Biological convergence is plausible, but each disorder has different residual coagulation, mucosal bleeding and treatment standards. Extrapolation across indications requires separate exposure response and safety evidence.<\/p>\n Upgrade evidence includes a large reduction in annualized treated bleeding, consistent effect with and without inhibitors, absence of thrombotic microangiopathy or thrombosis and practical laboratory monitoring. Breakthrough bleeding, interaction with rescue agents or narrow exposure margins would falsify differentiation.<\/p>\n Hemophilia A and B are caused by deficient factor VIII or IX and can be complicated by neutralizing inhibitors. Rebalancing therapies reduce endogenous anticoagulant activity to restore thrombin generation without replacing the missing factor. Activated protein C limits coagulation through factors Va and VIIIa, making it a mechanistically relevant but safety sensitive target.<\/p>\n This source gap catch up is a material hematology signal because a novel rebalancing antibody has reached confirmatory testing with monthly dosing. Direction remains uncertain until numerical Phase 1 and 2 data and a full protocol are available. Trial design will need rigorous baseline and adjudication because there is no concurrent control.<\/p>\n Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high from the listed company exchange filing and registry identifier. Confidence in Interpretation: moderate low because prior efficacy and safety numbers were not disclosed. Original publication date was 17 September 2026 and the item was recovered 22 September.<\/p>\n","protected":false},"excerpt":{"rendered":" Shanghai RAAS disclosed on 17 September that SR604 entered a single arm multicenter Phase 3 study for prophylaxis in hemophilia A or B patients with or without inhibitors. The registered dose is 0.4 mg…<\/p>\n","protected":false},"author":1,"featured_media":3380,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[844,846,845],"class_list":["post-3367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-hemophilia","tag-shanghai-raas","tag-sr604"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3367"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3367\/revisions"}],"predecessor-version":[{"id":3394,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3367\/revisions\/3394"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3380"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n